SCHEMBL20596131

SCHEMBL20596131

CCOC(=O)Cn1c(C(=O)c2ccc(Cl)cc2Cl)cn(Cc2nc3nc(Cl)ccc3[nH]2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 7/20 0.56
▸ ENPP2 Q13822 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ NR2E3 Q9Y5X4 1/20 0.34
▸ NCOR2 Q9Y618 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ TDP1 Q9NUW8 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ CASP1 P29466 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595861 0.89 MARS2 (0.67) MARS2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL20595905 0.88 MARS2 (0.56) MARS2MEN1KMT2ASMN1; SMN2POLB
SCHEMBL20595979 0.88 MARS2 (0.56) MARS2MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL20595919 0.87 MARS2 (0.56) MARS2MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL20595871 0.82 MARS2 (0.70) MARS2RAB9AALDH1A1POLBKDM4E
SCHEMBL20595944 0.81 MARS2 (0.51) MARS2SMN1; SMN2HSD17B10
SCHEMBL20596584 0.78 MARS2 (0.52) MARS2MEN1RAB9AKMT2AALDH1A1
SCHEMBL20595943 0.77 MARS2 (0.48) MARS2SMN1; SMN2HSD17B10
SCHEMBL20595966 0.76 MARS2 (0.77) MARS2MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL23391426 0.76 MARS2 (0.49) MARS2MEN1RAB9AKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO claimed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885ENPP2 2878/4885MEN1 1598/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885ENPP2 2643/4885MEN1 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback